Rein Therapeutics Inc. RNTX
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 13.03% | 10.16% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 16.18% | 32.10% | |||
| Operating Income | -16.18% | -32.10% | |||
| Income Before Tax | -9.20% | 82.14% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -9.20% | 81.74% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -9.20% | 81.74% | |||
| EBIT | -16.18% | -32.10% | |||
| EBITDA | -16.18% | -32.10% | |||
| EPS Basic | 64.31% | 80.94% | |||
| Normalized Basic EPS | 64.26% | -53.06% | |||
| EPS Diluted | 64.31% | 80.94% | |||
| Normalized Diluted EPS | 64.26% | -53.06% | |||
| Average Basic Shares Outstanding | 205.88% | -4.19% | |||
| Average Diluted Shares Outstanding | 205.88% | -4.19% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||